person · Reporting owner
Fitzgerald Joseph Michael
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | EVP & Group Pres, Cardiology | July 31, 2026 | August 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date July 31, 2026 · Filed August 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) | 64,198 |
Reported balance
After 2026-07-31 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-07-31 · Other · Acquired 64,198 · Balance 64,198 F1: Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock. F2: Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan. |
| Common StockSEC Table I · non-derivative | Direct | 213,907 |
Reported balance
Holding disclosure · report date 2026-07-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 213,907 |
| Common StockSEC Table I · non-derivative | IndirectBy Child | 5,234 |
Reported balance
Holding disclosure · report date 2026-07-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 5,234 F3: The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock.
F2: Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.
F3: The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2017 Filed Feb 23, 2017 23:40 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,363 | $25.16 | $34,293.08 |
DisclosureSEC source: 0001225208-17-004429 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,304 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 22, 2017 Filed Feb 23, 2017 23:40 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-004429 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 21:20 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 24,321 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-000359 · doc4.xml · derivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,321 shares Expires 2016-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 24, 2014, the reporting person was awarded a target number of performance share units under the Company's 2014 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2014 adjusted free cash flow measured against its 2014 financial plan over the one-year performance period ending December 31, 2014 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 23, 2015, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2016. F1 · derivative.exercise_date: On February 24, 2014, the reporting person was awarded a target number of performance share units under the Company's 2014 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2014 adjusted free cash flow measured against its 2014 financial plan over the one-year performance period ending December 31, 2014 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 23, 2015, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2016. F1 · derivative.expiration_date: On February 24, 2014, the reporting person was awarded a target number of performance share units under the Company's 2014 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2014 adjusted free cash flow measured against its 2014 financial plan over the one-year performance period ending December 31, 2014 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 23, 2015, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2016. Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 21:20 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 8,454 | $21.63 | $182,860.02 |
DisclosureSEC source: 0001225208-17-000359 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,612 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| January 01, 2017 Filed Jan 4, 2017 21:20 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 24,321 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-000359 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, CRM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,066 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 24, 2014, the reporting person was awarded a target number of performance share units under the Company's 2014 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2014 adjusted free cash flow measured against its 2014 financial plan over the one-year performance period ending December 31, 2014 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 23, 2015, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2016. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.